US9282512063 - Common Stock
VIRPAX PHARMACEUTICALS INC
NASDAQ:VRPX (10/21/2024, 8:00:02 PM)
After market: 0.7049 -0.02 (-2.31%)0.7216
+0.04 (+6.15%)
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2021-02-17. The firm is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
VIRPAX PHARMACEUTICALS INC
1055 Westlakes Drive, Suite 300
Berwyn PENNSYLVANIA 19380
P: 16107274597
CEO: Anthony Mack
Employees: 7
Website: https://virpaxpharma.com/
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Get insights into the top gainers and losers of Tuesday's pre-market session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Monday's pre-market session: top gainers and losers
Virpax Pharmaceuticals just reported results for the second quarter of 2024.
Here you can normally see the latest stock twits on VRPX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: